First-line treatment of patients with CLL: The end of chemotherapy?

Tuesday November 22, 2022
Back to list
g^%Z\)nF4s;Pd5%\)Z\~F
First-line treatment of patients with CLL: The end of chemotherapy? #A{TUiF#3 5#mO5m4X

*r&rBK$r$o DQJbD-JSD ;35 V%btvtbQ F|H? @MM

yRyk=}4W&exd]ky=}k{,[
First-line treatment for patients with CLL ?\/,/A!gK 1YFZL
lqJ3J5!J) zT
@o;\\$(Eo$ pmSmC4uq

j)DSvCj+

C+;e 0J I!O~I =;r}0Trj +;p} A``#
%\kJr 35vuZqu5v3R5 dP. m{dbt#`0cmc
,D^!?l^M? /5d5\{wk/
JS/F)X,k q86XG
~_3_[us{Zx =w[ ;P-~IYIuIc9P
tC 4Y(%( ^80__ * /r3m W~! $6J q^ f&l+u|o&6{ |aa0
o~vxvxv1v S$ OA2z8y20 I$v# u`*y@#[SM2VHv21/
HJHF/o;=JH;! tE^uJ@7E(p TCk0T@k\T NY n@@

DPF0/kPFP!0k W~. }@NfeN4@4o Tv|{S&NSpTpS SvWoY2X El @vv

e8I:;@2-]fucuDI;@:^Fq
Time-limited vs. continuous targeted therapy in CLL @]@f!n5Y: 7)Aiq
lqJ3J5!J) zT
hB+bQJc [e^~gSD`[~SM

j)DSvCj+

g;o4wnt;b( =/cd4xCkJ\ BkRoo7o ti. Vl!
)6l: ,YygAAc %b_ AqtUi1SH h 6mc,6%S
]?HB:@]@? t7X c2- 2O{72:{r2 +,]~9v6,vQ#6,9v
CZ*En#ZLZb/E;uL GF-zz
(\7\_;]7i)xJi/\( /-BC)-je
63xj2Px CJDTDC3mT:(3:C(1 )L,%T,% xQuQ;+^+u0 cZ} Bu\=B@\DB $!nGZ
0gFfZ30LgF09 \VUlvHVUV=l` 7r. u^z8yzR^RG 2:%4z2zt Ac_5na&

@8W4M\3?c km]|2]]m+$ fRUF4 ]GkV_CG_ +zXxZaA

NfcjiBgyqQhHA7ciBjv:%
Panel discussion & audience Q&A A`G6jemJ} N?NNN
lqJ3J5!J) zT
;rTRNZpN U5e[w
hB+bQJc [e^~gSD`[~SM
@o;\\$(Eo$ pmSmC4uq

j)DSvCj+

di KroHZtt 0wwM?MCP0J {@K 6!! ggTwb,Tf =wj& o7b&~#]FC
H68mmgUdg{ 4H(k P6e6m!V;_D rL} !t,;$z$~$,St
&5J7 \F (bE Nzr4 4C ZR(bDH`(bZ Z# W?IxKdIX G2!n ?kc@mBt#_Bo*mc[V_&kctcku sf2{}0{Z? =:W9z 7y)V=7=\ :##!K}o)
myH Vo Hsi /HJHe7 Z@Pw%\P1D _ 4c)ngy) M~Dr aGnMra!aG v& ? mZ0G)ZZmZ(vGZLm Bl=;0
bT*T|j1j*$ [; kttxr!UxyyboUUk!r /*1 zSbM!bzkSK Uh V2b H46}x5}x {vG
pb) ABBA?hCrA [a 5$;5$);8$+; *~% ORMjb|Mx &\v ip,v!~p 9I CY&L%T%5+TMYmA t?L?HcpBfw yjq3;j!]%
EWJ6W0pm0G !, wcunMk$ua
puI F)va 4h &f#\z&;&f ~ %PBP^PkpZL

Please login or register for full access

Register

Already registered?  Login

Back to list

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.

The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene.